Policy & Regulation Today - October 22, 2026

Judi Health Launches Medicare Part D Plan for Employers

Amazon, Google among self-funded employers joining CMS' prior auth pledge

GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure

GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to make copies of itself and viral proteins. This drug was licensed from antisense oligonucleotide specialist Ionis Pharmaceuticals. The post GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure appeared first on MedCity News.

BPC’s Comment on FDA’s Generative AI-Enabled Medical Devices Discussion Paper

KACH collaboration garners FDA approval of TBI diagnosis device; device recognized by TIME

Edwards Lifesciences wins FDA approval for PASCAL tricuspid repair